Evidence map›Paper›PMID 41121667›Full record

ArticleMicrobiologyOpen2025

The Role of Carbenicillin as an Inhibitor of the Biofilm Regulator CsgD in Salmonella Typhimurium.

Negar Narimisa, Amin Khoshbayan, Faramarz Masjedian Jazi, Shabnam Razavi

Abstract read
In one paragraph

Article in MicrobiologyOpen, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Negar NarimisaMicrobial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Amin KhoshbayanMicrobial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1094-5812
Faramarz Masjedian JaziMicrobial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Shabnam RazaviMicrobial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-4566-3089

Funding

This paper was funded by Microbial Biotechnology Research Center (Iran University of Medical Sciences) by a research grant (No. 32437, and Ethics Approval ID: IR.IUMS.REC.1403.1183), for which we are very grateful.
6 · The paper itself

Abstract

Salmonella Typhimurium, a major foodborne pathogen, forms biofilms that enhance its environmental persistence and resistance to antibiotics, presenting significant public health challenges. The CsgD protein, a key transcriptional regulator, orchestrates biofilm formation by regulating curli fimbriae and cellulose production. This study aimed to identify and evaluate potential CsgD inhibitors to disrupt S. Typhimurium biofilms using a combination of computational and experimental methodologies. Molecular docking was performed to screen 145 FDA-approved antibiotics from DrugBank against the CsgD protein. Carbenicillin, identified as a top candidate, was further analyzed through 100 ns molecular dynamics simulations to assess the stability of the carbenicillin-CsgD complex. Experimental evaluations determined the minimum biofilm inhibitory concentration (MBIC), and minimum biofilm eradication concentration (MBEC) of carbenicillin against S. Typhimurium isolates. Biofilm structure and curli production were examined using scanning electron microscopy (SEM) and Congo red agar assays, respectively. Molecular docking revealed carbenicillin's high binding affinity to CsgD. Molecular dynamics simulations confirmed the structural stability of the carbenicillin-CsgD complex. Experimental assays established MBIC and MBEC at 1 and 4 μg/mL, respectively. SEM analysis showed morphological changes and disrupted biofilm architecture at 0.5-1 μg/mL carbenicillin, while Congo red agar assays demonstrated dose-dependent suppression of curli production. Carbenicillin exhibits significant potential as a CsgD-targeted anti-biofilm agent, providing a foundation for novel therapeutic strategies to combat S. Typhimurium infections and address their public health burden.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsBiofilmsCarbenicillinSalmonella typhimuriumTrans-ActivatorsMicrobial Sensitivity TestsMolecular Docking SimulationMolecular Dynamics SimulationAnti-Bacterial AgentsBacterial ProteinsCarbenicillinTrans-ActivatorsbiofilmcarbenicillinCsgDmolecular dockingSalmonella Typhimurium

Identifiers

PMID41121667
PMCPMC12540931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.